




PHARMACEUTICAL 2020

Calithera Biosciences Inc.
Rank 102 of 358





RealRate

PHARMACEUTICAL 2020

Calithera Biosciences Inc. Rank 102 of 358



The relative strengths and weaknesses of Calithera Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Calithera Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 104% points. The greatest weakness of Calithera Biosciences Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 38% points.

The company's Economic Capital Ratio, given in the ranking table, is 159%, being 123% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	159,796
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	19,624
Liabilities, Non-Current	6,718
Other Assets	7,980
Other Compr. Net Income	155
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	3,035
Property and Equipment	992
Research and Development	76,290
Selling, General and Administrative Expense	16,605

Output Variable	Value in 1000 USD
Assets	168,768
Liabilities	26,342
Expenses	92,895
Revenues	3,035
Stockholders Equity	142,426
Net Income	-89,860
Comprehensive Net Income	-89,782
Economic Capital Ratio	159%